October 27th 2025
The anti–CTLA-4 antibody combination achieved an ORR of 34.8%, with 8 partial responses, in patients with pretreated microsatellite-stable mCRC.
SIRFLOX Regimen Delays Liver Progression in Metastatic Colorectal Cancer
February 25th 2016The addition of selective internal radiation therapy with yttrium-90 resin microspheres to standard FOLFOX chemotherapy did not improve progression-free survival in patients with metastatic colorectal cancer, but it did significantly delay disease progression in the liver.
Neoadjuvant Treatment for Surgically Resectable Metastatic Colorectal Cancer
January 16th 2016Here, we review the studies that have explored different treatment regimens, therapeutic sequencing, and biologic inclusions for the treatment of these patients, with neoadjuvant intent. We also describe how we have established our own treatment paradigm for the management of potentially curable metastatic colorectal cancer.
The Role of HIPEC in Gastrointestinal Malignancies: Controversies and Conclusions
July 15th 2015It is clear that in a subset of patients with GI malignancies, particularly the low-grade appendiceal neoplasms, CS + HIPEC can result in improved outcomes and in some cases, long-term remission and occasionally cure.